ecropolis

sick asian young woman sneezing into tissue paper while covered with a blanket

January 19, 2023

Long COVID: major findings, mechanisms and recommendations | Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome | Detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination | Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19 | Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019

January 19, 2023 Read More »

January 12, 2023

Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study | Effectiveness of the Bivalent mRNA Vaccine in Preventing Severe COVID-19 Outcomes: An Observational Cohort Study | 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection | Increasing Ventilation Reduces Sars-Cov-2 Airborne Transmission In Schools | Use of Carbon Dioxide Monitoring to Assess Ventilation at a National Infectious Diseases Conference

January 12, 2023 Read More »

January 5, 2023

Virological characteristics of the SARS-CoV-2 XBB variant | SARS-CoV-2 infection and persistence in the human body | Long-term cardiovascular outcomes of COVID-19 | Heart-disease risk soars | Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants | Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines |
Time to negative PCR conversion among high-risk patients | The Fc-effector function of COVID-19 convalescent plasma | Infectiousness of SARS-CoV-2 breakthrough infections and reinfections

January 5, 2023 Read More »

December 29, 2022

Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron | Structural brain changes in post-acute COVID-19 patients | Persistent post–COVID-19 smell loss | Persistent symptoms and sequelae after SARS-CoV-2 infection | VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 | Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System | Molnupiravir plus usual care versus usual care alone as early treatment for adults | Higher dose corticosteroids in hospitalized COVID-19 patients | FDA approves Roche’s Actemra (tocilizumab) for the treatment of COVID-19 | Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine | Canine real-time detection of SARS-CoV-2 infections | Clinical Validation of a Novel T-Cell Receptor | Modelling the adjustment of COVID-19 response | Two masks can be worse than one: N95 respirator failure caused by an overlying face mask | Airflow Patterns in Double-Occupancy Patient Rooms | The epidemiology of long COVID in US adults

December 29, 2022 Read More »

December 22, 2022

Immunological dysfunction persists for 8 months |
Clinical Features and Burden of Post-Acute Sequelae of SARS-CoV-2 Infection |
Demonstration of stable clusters of symptoms | Longitudinal Analysis of T cells in COVID-19 |
Reconsideration of anti-nucleocapsid IgG antibody | Early Estimates of Bivalent mRNA Vaccine |
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated
Hospitalization | Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations |
COVID-19 Convalescent Plasma Outpatient Therapy | Bacterial Co-infection and Empirical Antibiotic Therapy in Patients |
Similar SARS-CoV-2 Ct value distributions in anterior nares versus nasopharyngeal samples |
Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics | The WHO estimates of excess mortality associated with the COVID-19 pandemic |
Impact of SARS-CoV-2 variants on inpatient clinical outcome | Association of Time to Surgery After COVID-19 Infection

December 22, 2022 Read More »

Receive updates about Parasites without Borders initiatives, developments, and learn more about parasites by subscribing to our periodic newsletter.


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Parasites Without Borders

A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.

Donate to Parasites Without Borders Today!

Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States.

Scroll to Top